A user experienced hairline improvement after four weeks on 1.5mg dutasteride but had side effects like reduced libido and sensitive nipples. They plan to switch to finasteride to manage these side effects.
RU58841 is considered effective by some users, but finasteride and minoxidil are commonly used with varying dosages to manage side effects. Users report different experiences with treatments like pyrilutamide, fluridil, and RU58841, with some seeing results and others not.
The conversation is about finding a reliable Chinese source for pyrilutamide or RU58841, ideally with a third-party Certificate of Analysis from Janoshik Analytical. The user is seeking recommendations for these hair loss treatments.
Increasing dutasteride from 0.5mg to 2.5mg may not significantly reduce hair loss and can cause side effects like sleep disturbances and brain fog. Many users find 0.5mg effective enough, while some switch to topical finasteride due to side effects.
The conversation discusses interest in peptides for hair loss, specifically mentioning ahkCU and ghkCU. A user is considering adding ghkCU to their treatment regimen.
The user switched from Finasteride to topical Dutasteride, Pyrilutamide, and Minoxidil due to hair loss, then decided to switch to oral Dutasteride because of pregnancy concerns. They are considering the frequency of oral Dutasteride use, with suggestions of using it a few times a week for better results and fewer side effects.
The user plans to switch from minoxidil to finasteride or dutasteride for hair loss, while managing hormones with aromatase inhibitors and SHBG blockers. They seek advice on the best options for these treatments, considering past side effects and future therapies.
The conversation is about the effectiveness and trustworthiness of Pyrilutamide hair loss treatment sold by Hairlisciously, with concerns about product purity and a request for alternative suppliers. No specific treatments were confirmed to be used by participants.
Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.
The user is hesitant to start using finasteride again due to past side effects experienced between 2015-2018. They have had the medication for a month but are afraid to begin treatment.